Bio-Techne Corporation (TE1.F)
| Previous close | 64.00 |
| Open | 62.50 |
| Bid | 61.00 x N/A |
| Ask | 61.50 x N/A |
| Day's range | 62.50 - 62.50 |
| 52-week range | 49.40 - 80.50 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 9.824B |
| Beta (5Y monthly) | 1.22 |
| PE ratio (TTM) | 47.71 |
| EPS (TTM) | 1.31 |
| Earnings date | 01 May 2024 |
| Forward dividend & yield | 0.30 (0.47%) |
| Ex-dividend date | 09 Feb 2024 |
| 1y target est | 549.60 |
PR NewswireBIO-TECHNE TO HOST CONFERENCE CALL ON MAY 1, 2024, TO ANNOUNCE THIRD QUARTER FISCAL 2024 FINANCIAL RESULTS
Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, May 1, 2024, at 8:00 a.m. CDT to review third quarter fiscal 2024 financial results.
- PR Newswire
BIO-TECHNE SURPASSES 10,000 PEER-REVIEWED PUBLICATIONS CITING RNAscope TECHNOLOGY
Bio-Techne Corporation (NASDAQ: TECH) today announced that Advanced Cell Diagnostics (ACD), part of Bio-Techne's Spatial Biology Division, has surpassed 10,000 peer-reviewed publications referencing the use and application of RNAscope™ ISH technology. Over 50% of these publications were released in the past 3 years, as increasing global customer awareness and expanded market adoption solidify ACD's leadership in spatial biology applications.
PR NewswireBIO-TECHNE TO PRESENT AT THE 2024 AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) CONFERENCE
Bio-Techne Corporation (NASDAQ:TECH) today announced it will showcase its portfolio of solutions to advance cancer research from target discovery to cell therapy development at the upcoming annual meeting of the American Association for Cancer Research (AACR), taking place April 5-10, 2024, in San Diego, California.
